Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Everolimus 5Octreotide 4Leucovorin 3Capecitabine 3vatalanib 2Trastuzumab 2Temozolomide 2Oxaliplatin 2Melphalan 2Fluorouracil 2Biological Therapy 2Bevacizumab 2tipifarnib 1temsirolimus 1romidepsin 1regorafenib 1pentetreotide 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Irinotecan 1Interleukin-12 Subunit p35 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × regorafenib × Endocrine × Clear all
NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

University of Southern California

Phase 2 Completed
3 enrolled 7 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡